SPY295.44+0.56 0.19%
DIA244.88-0.14 -0.06%
IXIC9,324.59+39.71 0.43%

Lexicon Pharma Highlights Will Present Preclinical Efficacy Data On Telotristat Ethyl's Antiproliferative Effects Against Various Cancer Cell Lines

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell

Benzinga · 05/13/2020 22:01

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines that were published online in conjunction with the American Society of Clinical Oncology (ASCO) 2020 annual meeting (May 29 - June 2, 2020). XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use.

Tumor growth inhibition when exposed to telotristat ethyl was most pronounced in the liposarcoma cell line, followed by the colon cancer and cholangiocarcinoma cell lines. 

“We are pleased that this preclinical study demonstrated that telotristat ethyl has antitumor effect in various cancer types,” said Praveen Tyle, Ph.D, executive vice president, research and development of Lexicon. “Today’s data support the conduct of additional studies to examine telotristat ethyl’s effect on tryptophan hydroxylase positive cancers.”